Anand Pathak MD PhD, MPH
Public Health & General Preventive Medicine
Medical Officer, FDA
Join to View Full Profile
10903 New Hampshire BlvdSilver Spring, MD 20993
Phone+1 513-313-8620
Dr. Pathak is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Visionary thought leader in molecular diagnostics for precision oncology and cutting edge molecular diagnostics cancer screening.
Education & Training
University of Michigan School of Public HealthResidency, Public Health and General Preventive Medicine, 2010 - 2012
Jewish Hospital of CincinnatiResidency, Internal Medicine, 2008 - 2009
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 2007 - 2008
University of Cincinnati College of MedicineClass of 2007
Certifications & Licensure
MI State Medical License 2012 - 2025
American Board of Preventive Medicine Public Health & General Preventive Medicine
Awards, Honors, & Recognition
- University of Michigan Phi Kappa Phi Phi Kappa Phi
Publications & Presentations
PubMed
- 2 citationsUS Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locall...Asma Dilawari, James Buturla, Christy Osgood, Xin Gao, Wei Chen
Journal of Clinical Oncology. 2024-12-01 - 7 citationsUS Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative,-Mutated Advanced or Me...Mirat Shah, Hima Lingam, Xin Gao, Haley Gittleman, Mallorie H Fiero
Journal of Clinical Oncology. 2024-04-01 - 10 citationsFDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With-Mutated Metastatic Castration-Resistant Prostate Cancer.Jaleh Fallah, Jianjin Xu, Chana Weinstock, Michael H Brave, Erik Bloomquist
Journal of Clinical Oncology. 2024-02-10
Press Mentions
50% of Children with Cancer Are Left Undiagnosed and Untreated: StudyMarch 6th, 2019
Public Workshop - Next Generation Sequencing-Based Oncology Panels, February 25, 2016February 25th, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
